

# OIE Reference Laboratory Reports Activities

## *Activities in 2021*

**This report has been submitted : 2022-01-27 23:02:40**

<b>Name of disease (or topic) for which you are a designated OIE Reference Laboratory:</b>	Infection with yellow head virus genotype 1
<b>Address of laboratory:</b>	CSIRO Australian Centre for Disease Preparedness 5 Portarlington Road Private Bag 24 (Ryrie Street) Geelong 3220, Victoria AUSTRALIA
<b>Tel.:</b>	+61-3 52 27 55 11
<b>Fax:</b>	+61-3 52 27 55 55
<b>E-mail address:</b>	nick.moody@csiro.au
<b>Website:</b>	www.csiro.au
<b>Name (including Title) of Head of Laboratory (Responsible Official):</b>	Prof Trevor Drew ACDP Director
<b>Name (including Title and Position) of OIE Reference Expert:</b>	Nick Moody Group Leader - ACDP Fish Diseases Laboratory
<b>Which of the following defines your laboratory? Check all that apply:</b>	Governmental

**ToR 1: To use, promote and disseminate diagnostic methods validated according to OIE Standards**

1. Did your laboratory perform diagnostic tests for the specified disease/topic for purposes such as disease diagnosis, screening of animals for export, surveillance, etc.? (Not for quality control, proficiency testing or staff training)

Yes

Diagnostic Test	Indicated in OIE Manual (Yes/No)	Total number of test performed last year	
		Nationally	Internationally
Indirect diagnostic tests			
0	0	0	0
Direct diagnostic tests			
AFDL YHV1 RT-qPCR	No	70	
OIE Protocol 2 RT-nPCR	Yes	6	

**ToR 2: To develop reference material in accordance with OIE requirements, and implement and promote the application of OIE Standards.  
To store and distribute to national laboratories biological reference products and any other reagents used in the diagnosis and control of the designated pathogens or disease.**

2. Did your laboratory produce or supply imported standard reference reagents officially recognised by the OIE?

No

3. Did your laboratory supply standard reference reagents (non OIE-approved) and/or other diagnostic reagents to OIE Member Countries?

Yes

Type of reagent available	Related diagnostic test	Produced/ provide	Amount supplied nationally (ml, mg)	Amount supplied internationally (ml, mg)	No. of recipient OIE Member Countries	Region of recipients
Gamma-irradiated YHV1-infected prawn haemolymph	Molecular testing	Provide	1.0ml	0.5ml	2	<input type="checkbox"/> Africa <input type="checkbox"/> Americas <input checked="" type="checkbox"/> Asia and Pacific <input type="checkbox"/> Europe <input type="checkbox"/> Middle East

4. Did your laboratory produce vaccines?

No

5. Did your laboratory supply vaccines to OIE Member Countries?

No

***ToR 3: To develop, standardise and validate, according to OIE Standards, new procedures for diagnosis and control of the designated pathogens or diseases***

6. Did your laboratory develop new diagnostic methods validated according to OIE Standards for the designated pathogen or disease?

No

7. Did your laboratory develop new vaccines according to OIE Standards for the designated pathogen or disease?

No

***ToR 4: To provide diagnostic testing facilities, and, where appropriate, scientific and technical advice on disease control measures to OIE Member Countries***

8. Did your laboratory carry out diagnostic testing for other OIE Member Countries?

No

9. Did your laboratory provide expert advice in technical consultancies on the request of an OIE Member Country?

No

**ToR 5: To carry out and/or coordinate scientific and technical studies in collaboration with other laboratories, centres or organisations**

10. Did your laboratory participate in international scientific studies in collaboration with OIE Member Countries other than the own?

No

**ToR 6: To collect, process, analyse, publish and disseminate epizootiological data relevant to the designated pathogens or diseases**

11. Did your Laboratory collect epizootiological data relevant to international disease control?

No

If the answer is no, please provide a brief explanation of the situation:

No. Reduced laboratory testing capability and freight transport nationally and internationally due to COVID-19

12. Did your laboratory disseminate epizootiological data that had been processed and analysed?

No

If the answer is no, please provide a brief explanation of the situation:

No. Reduced laboratory testing capability and freight transport nationally and internationally due to COVID-19

**13. What method of dissemination of information is most often used by your laboratory?  
(Indicate in the appropriate box the number by category)**

a) Articles published in peer-reviewed journals: 0

b) International conferences: 0

c) National conferences: 0

d) Other:  
(Provide website address or link to appropriate information) 0

**ToR 7: To provide scientific and technical training for personnel from OIE Member Countries****To recommend the prescribed and alternative tests or vaccines as OIE Standards**

14. Did your laboratory provide scientific and technical training to laboratory personnel from other OIE Member Countries?

No

**ToR 8: To maintain a system of quality assurance, biosafety and biosecurity relevant for the pathogen and the disease concerned**

15. Does your laboratory have a Quality Management System?

Yes

Quality management system adopted	Certificate scan (PDF, JPG, PNG format)
ISO 17025 & ISO 17043	NATA ISO 17025 & 17043 Certificates.pdf
ISO 9001	BSI ISO 9001 Certificate.pdf
ISO 14001	BSI ISO 14001 Certificate.pdf

16. Is your quality management system accredited?

Yes

Test for which your laboratory is accredited	Accreditation body
20.14 Virology 01 Diagnostic virology - non-cultural (immunological) methods of detection 02 Diagnostic virology - cultural methods of detection and identification of organisms Including Innocuity testing 05 Quantitative procedures	NATA (ILAC affiliated)
20.80 Molecular Diagnostics For companion animals, production animals, production avian species, aquatic animals, equine species and avian species 01 Identification by extraction and amplification 02 Sequencing 03 Genotyping 99 Other - Testing for rabies and rabies related lyssaviruses on human specimens by molecular techniques	NATA (ILAC affiliated)
Detection and identification of viruses (PCR - Quantitative (qPCR); Polymerase chain reaction (PCR))	NATA (ILAC affiliated)
Accreditation No: 13546 (scope last change 2021)	

17. Does your laboratory maintain a "biorisk management system" for the pathogen and the disease concerned?

Yes

(See *Manual of Diagnostic Tests and Vaccines for Terrestrial Animals, Chapter 1.1.4*)

**ToR 9: To organise and participate in scientific meetings on behalf of the OIE**

18. Did your laboratory organise scientific meetings on behalf of the OIE?

No

19. Did your laboratory participate in scientific meetings on behalf of the OIE?

Yes

Title of event	Date (mm/yy)	Location	Role (speaker, presenting poster, short communications)	Title of the work presented
3rd meeting of the Steering Committee of the Regional Collaboration Framework on Aquatic Animal Health	12/21	Online	Speaker	eDNA for aquatic pathogen detection OIE ad Hoc Group on Tilapia lake virus: Interlaboratory Comparability Program

**ToR 10: To establish and maintain a network with other OIE Reference Laboratories designated for the same pathogen or disease and organise regular inter-laboratory proficiency testing to ensure comparability of results**

20. Did your laboratory exchange information with other OIE Reference Laboratories designated for the same pathogen or disease?

Not applicable (Only OIE Reference Lab. designated for disease)

21. Was your laboratory involved in maintaining a network with OIE Reference Laboratories designated for the same pathogen or disease by organising or participating in proficiency tests?

Not applicable (Only OIE Reference Lab. designated for disease)

22. Did your laboratory collaborate with other OIE Reference Laboratories for the same disease on scientific research projects for the diagnosis or control of the pathogen of interest?

Not applicable (Only OIE Reference Lab. designated for disease)

**ToR 11: To organise inter-laboratory proficiency testing with laboratories other than OIE Reference Laboratories for the same pathogens and diseases to ensure equivalence of results**

23. Did your laboratory organise or participate in inter-laboratory proficiency tests with laboratories other than OIE Reference Laboratories for the same disease?

Yes

Note: See Interlaboratory test comparisons in: Laboratory Proficiency Testing at: <http://www.oie.int/en/our-scientific-expertise/reference-laboratories/proficiency-testing> see point 1.3

Purpose for inter-laboratory test comparisons <sup>1</sup>	No. participating laboratories	Region(s) of participating OIE Member Countries
National Aquatic Program 2021: Diseases of crustacea	12	<input type="checkbox"/> Africa <input type="checkbox"/> Americas <input checked="" type="checkbox"/> Asia and Pacific <input type="checkbox"/> Europe <input type="checkbox"/> Middle East
Asia-Pacific Laboratories: Disease of crustacea	21	<input type="checkbox"/> Africa <input type="checkbox"/> Americas <input checked="" type="checkbox"/> Asia and Pacific <input checked="" type="checkbox"/> Europe <input type="checkbox"/> Middle East

### **ToR 12: To place expert consultants at the disposal of the OIE**

24. Did your laboratory place expert consultants at the disposal of the OIE?

Yes

Kind of consultancy	Location	Subject (facultative)
ad hoc Group member	Online	ad hoc Group on tilapia lake virus
ad hoc Group member		ad hoc Group on the OIE Manual of Diagnostic Tests for Aquatic Animals

25. Additional comments regarding your report:

Due to COVID-19, ACDP has continued to work with limited operational capacity throughout 2021 (for example, adopting roster arrangements for staff site access, reduced site access to ensure physical distancing, no international travel and visitors unable to attend site for most of the year). This has significantly limited ACDP's capacity to carry out planned research and conduct training and has limited some types of diagnostic submissions to the laboratory.